Academics at Texas Tech University did a review of the PubMed/MEDLINE database on pemetrexed (Alimta) articles. They conclude that “Pemetrexed should be used as a standard of care for unresectable MPM [malignant pleural mesothelioma] and recurrent metastatic NSCLC [non-small cell lung cancer].” They also mention decreasing toxicity of the drug by giving the patient steroids and vitamins.